CareDx has seen its share price move sharply in recent years, which puts a spotlight on whether the current US$61.37 level is aligned with the cash flows the business can realistically generate. For anyone looking at the stock today, the key issue is how that share price compares with an intrinsic value estimate built from its cash flows.
- Over the past 3 years, CareDx has delivered a very large total return of about 7x, which raises the question of how much future cash flow is already reflected in the current valuation.
- The business model depends heavily on turning its transplant testing and related services into consistent cash inflows. This can shape expectations for how quickly operating cash flow might scale relative to the capital required to support that growth.
- Prefer to judge CareDx on earnings? See why CareDx's 28.6x P/E tells a different valuation story.
The stock's next move may depend on whether its recent share price level is supported by the intrinsic value suggested by a Discounted Cash Flow (DCF) view of CareDx's cash flows.
If you want to explore the same cash flow question you are asking of CareDx across a broader set of ideas, scan through the 30 high quality undervalued stocks
Does CareDx Look Undervalued on Cash Flow?
The Discounted Cash Flow (DCF) model used here looks at the cash CareDx could return to shareholders over time and brings those figures back to today. CareDx has generated last twelve month free cash flow of about $83.9 million, and the scenario used in the model assumes that these cash flows continue to grow from this base rather than shrink.
Analysts contributing to the DCF expect CareDx's annual free cash flow to be higher by the early 2030s, with growth rates that taper from stronger increases in the nearer years to more modest expansion further out. When these projected cash streams are discounted back and compared with the current share price of $61.37, the DCF view points to an estimated intrinsic value that is substantially above where the stock trades today. Find out what CareDx could be worth using our Discounted Cash Flow (DCF) estimate.
The CareDx Narrative: What Would Justify Today's Price?
Narratives for CareDx pick up where the DCF puzzle leaves off by spelling out which specific paths for future growth, margins and earnings would need to hold for the share price to sit meaningfully above or below today's level on Simply Wall St's Community page. Instead of a single output from a ratio or model, Narratives map the underlying future those numbers rely on, so you can watch how CareDx's actual progress lines up with that script over time.
Community views on CareDx split between those who see more upside in the story and those who think expectations already look stretched.
Bull case: roughly fairly valued
"The expanded push into digital health software, remote patient monitoring, and data analytics leverages the ongoing transition toward value-based, preventive healthcare..."
Discover why this Narrative puts CareDx at roughly fairly valued.
Bear case: 53% overvalued
"Imminent shifts in reimbursement policies and industry consolidation threaten CareDx's pricing power, gross margins, and future revenue scalability..."
Explore why this Narrative puts CareDx at 53% overvalued.
One more question for CareDx that the valuation does not answer
Before you rely too heavily on any cash flow model for CareDx, it helps to weigh the specific risk checks our research has flagged and decide how they sit with your own tolerance. Take a closer look at 4 warning signs (2 major) before settling on a valuation.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com